infl
uen
za
well
known
among
gen
eral
pub
lic
gard
epi
dem
ic
oc
currenc
ci
tion
di
abl
re
pira
ry
ill
ness
ev
er
peo
ple
con
sider
abli
less
awar
size
di
tri
bution
eco
nom
ic
bur
den
im
pose
vi
ru
cent
studi
med
cal
care
use
lat
ed
flu
en
za
unit
ed
king
dom
dur
ing
found
ab
lute
term
adult
age
year
flu
en
zare
lat
ed
phi
si
cian
visit
clin
cal
com
pli
ca
tion
greater
drug
use
chil
dren
el
der
ly
studi
ex
plore
costef
fec
tive
treat
ing
oth
er
wise
heal
thi
adult
pop
u
la
tion
flu
en
za
dur
ing
typ
cal
nu
al
epi
dem
ic
pe
ri
od
treat
ment
ter
ven
tion
ve
ti
gat
ed
os
eltamivir
zanamivir
neur
amin
dase
hibitor
work
specif
cal
ly
flu
en
za
type
b
hibit
ing
rep
li
ca
tion
vi
ru
re
pi
ra
ry
tract
ad
min
tere
twice
dai
ly
day
oseltamivir
tak
en
oral
ly
zanamivir
hale
us
ing
spe
cial
de
vice
treat
ment
need
ini
ti
ed
h
set
symp
tom
ef
fi
ca
cy
usual
ly
ci
ed
mild
tran
sient
side
ef
fect
use
pre
scribe
two
com
pet
ing
prod
uct
ex
ist
market
aman
ta
dine
ri
man
ta
dine
uk
socal
ion
chan
nel
block
er
work
flu
en
za
ci
ed
ga
tro
te
ti
nal
cen
tral
ner
vou
sy
tem
side
ef
fect
aman
ta
dine
rec
om
mend
ed
na
tion
al
sti
tute
clin
cal
ex
cel
lenc
nice
flu
en
za
treat
ment
giv
en
flu
en
za
ca
es
treat
ed
overthecoun
ter
otc
med
ca
tion
chose
com
pare
usu
al
care
oseltamivir
zanamivir
meth
od
phar
coeco
nom
ic
de
ci
sionan
lyt
ic
mod
el
cor
po
rat
ing
firstand
sec
ondor
der
mont
car
lo
sim
u
la
tion
de
velop
ve
ti
gate
costef
fec
tive
ness
costutil
ty
heal
thi
adult
pop
u
la
tion
year
per
spec
tive
health
care
pay
er
uk
na
tion
al
health
ser
vice
nh
ci
etal
perspec
tive
con
sid
er
cost
health
bene
fit
gard
less
ex
pe
ri
enc
pur
po
es
anal
si
usu
al
care
de
fine
symp
tom
ic
treat
ment
base
line
strat
e
gy
sinc
main
stan
dard
prac
tice
flu
en
za
treat
ment
de
spite
avail
abil
ty
al
ter
na
tive
de
ci
sion
tree
fig
vi
su
al
ize
mor
bid
ty
mor
tal
ty
due
flu
en
za
spec
fie
com
pli
ca
tion
model
start
gen
er
al
prac
ti
tio
ner
gp
fice
sinc
os
eltamivir
zanamivir
avail
abl
gp
pre
scription
otc
med
ca
tion
treatment
op
tion
usu
al
care
cur
rent
practic
os
eltamivir
ter
ven
tion
zanamivir
ter
ven
tion
ef
fect
inter
ven
tion
os
eltamivir
zanamivir
achiev
ad
di
tion
use
otc
med
ca
tion
use
se
lect
ed
otc
medicin
par
ac
et
mol
ti
tu
sive
al
low
clin
cal
tri
al
di
abl
symp
tom
mod
el
di
tin
guish
es
tween
two
pe
ri
od
start
treat
ment
h
set
symp
tom
af
ter
h
well
tween
flu
en
zapo
tive
flu
en
zaneg
tive
ca
es
di
ag
no
tic
certain
ty
sinc
treat
ment
neur
amini
dase
hibitor
con
firm
ef
fectiv
flu
en
za
vi
ru
tak
en
h
set
symp
tom
cost
os
eltamivir
zanamivir
treat
ment
incur
al
though
im
prove
ment
health
come
fect
ed
di
vid
infl
uen
za
well
known
among
gen
eral
pub
lic
gard
epi
dem
ic
oc
currenc
ci
tion
di
abl
re
pira
ry
ill
ness
ev
er
peo
ple
con
sider
abli
less
awar
size
di
tri
bution
eco
nom
ic
bur
den
im
pose
vi
ru
cent
studi
med
cal
care
use
lat
ed
flu
en
za
unit
ed
king
dom
dur
ing
found
ab
lute
term
adult
age
year
flu
en
zare
lat
ed
phi
si
cian
visit
clin
cal
com
pli
ca
tion
greater
drug
use
chil
dren
el
der
ly
studi
ex
plore
costef
fec
tive
treat
ing
oth
er
wise
heal
thi
adult
pop
u
la
tion
flu
en
za
dur
ing
typ
cal
nu
al
epi
dem
ic
pe
ri
od
treat
ment
ter
ven
tion
ve
ti
gat
ed
os
eltamivir
zanamivir
neur
amin
dase
hibitor
work
specif
cal
ly
flu
en
za
type
b
hibit
ing
rep
li
ca
tion
vi
ru
re
pi
ra
ry
tract
ad
min
tere
twice
dai
ly
day
oseltamivir
tak
en
oral
ly
zanamivir
hale
us
ing
spe
cial
de
vice
treat
ment
need
ini
ti
ed
h
set
symp
tom
ef
fi
ca
cy
usual
ly
ci
ed
mild
tran
sient
side
ef
fect
use
pre
scribe
two
com
pet
ing
prod
uct
ex
ist
market
aman
ta
dine
ri
man
ta
dine
uk
socal
ion
chan
nel
block
er
work
flu
en
za
ci
ed
ga
tro
te
ti
nal
cen
tral
ner
vou
sy
tem
side
ef
fect
aman
ta
dine
rec
om
mend
ed
na
tion
al
sti
tute
clin
cal
ex
cel
lenc
nice
flu
en
za
treat
ment
giv
en
flu
en
za
ca
es
treat
ed
overthecoun
ter
otc
med
ca
tion
chose
com
pare
usu
al
care
oseltamivir
zanamivir
phar
coeco
nom
ic
de
ci
sionan
lyt
ic
mod
el
cor
po
rat
ing
firstand
sec
ondor
der
mont
car
lo
sim
u
la
tion
de
velop
ve
ti
gate
costef
fec
tive
ness
costutil
ty
heal
thi
adult
pop
u
la
tion
year
per
spec
tive
health
care
pay
er
uk
na
tion
al
health
ser
vice
nh
ci
etal
perspec
tive
con
sid
er
cost
health
bene
fit
gard
less
ex
pe
ri
enc
pur
po
es
anal
si
usu
al
care
de
fine
symp
tom
ic
treat
ment
base
line
strat
e
gy
sinc
main
stan
dard
prac
tice
flu
en
za
treat
ment
de
spite
avail
abil
ty
al
ter
na
tive
de
ci
sion
tree
fig
vi
su
al
ize
mor
bid
ty
mor
tal
ty
due
flu
en
za
spec
fie
com
pli
ca
tion
model
start
gen
er
al
prac
ti
tio
ner
gp
fice
sinc
os
eltamivir
zanamivir
avail
abl
gp
pre
scription
otc
med
ca
tion
treatment
op
tion
usu
al
care
cur
rent
practic
os
eltamivir
ter
ven
tion
zanamivir
ter
ven
tion
ef
fect
inter
ven
tion
os
eltamivir
zanamivir
achiev
ad
di
tion
use
otc
med
ca
tion
use
se
lect
ed
otc
medicin
par
ac
et
mol
ti
tu
sive
al
low
clin
cal
tri
al
di
abl
symp
tom
mod
el
di
tin
guish
es
tween
two
pe
ri
od
start
treat
ment
h
set
symp
tom
af
ter
h
well
tween
flu
en
zapo
tive
flu
en
zaneg
tive
ca
es
di
ag
no
tic
certain
ty
sinc
treat
ment
neur
amini
dase
hibitor
con
firm
ef
fectiv
flu
en
za
vi
ru
tak
en
h
set
symp
tom
cost
os
eltamivir
zanamivir
treat
ment
incur
al
though
im
prove
ment
health
come
fect
ed
di
vidstudi
pop
u
la
tion
one
compli
ca
tion
time
sume
port
ed
com
pli
ca
tion
oc
cur
differ
ent
pa
tient
treat
ment
neur
amin
idas
hibitor
sume
ef
fect
ci
denc
com
pli
ca
tion
cours
mean
baselin
usu
al
care
ter
ven
tion
neuramin
dase
hibitor
proba
bil
tie
ho
pi
tal
iza
tion
mor
tal
ty
due
bron
chi
ti
pneu
mo
nia
com
pli
ca
tion
de
vel
op
due
lim
ed
data
avail
abil
ty
fur
ther
sump
tion
made
ho
pi
tal
iza
tion
sume
bron
chi
ti
mor
tal
ty
rate
due
com
pli
ca
tion
low
er
flu
en
za
self
im
pact
un
certain
ty
sur
round
ing
data
use
vari
abl
prob
bil
ty
com
pli
ca
tion
hospi
tal
iza
tion
mor
tal
ty
de
ter
mine
prob
bili
tic
sen
si
tiv
ty
anal
si
sec
ondor
der
mont
car
lo
sim
u
la
tion
cent
ev
denc
clin
ical
prac
tice
com
pli
anc
zanamivir
sue
par
tic
u
lar
ly
el
der
ly
pa
tient
jor
ty
found
dif
fi
cul
ty
load
ing
de
vice
ev
er
clin
cal
tri
al
heal
thi
adult
pop
u
la
tion
port
ed
high
rate
com
pli
anc
fore
com
plianc
zanamivir
sume
po
af
ter
ap
pli
ing
clu
sion
ex
clu
sion
cri
te
ria
qual
ty
studi
come
pa
ram
e
ter
mea
sure
compa
ra
bil
ty
across
stud
i
small
fraction
triev
lit
er
ture
use
fi
nal
data
sourc
mod
el
clin
ical
tri
al
data
lit
er
ture
data
compl
ment
ed
sump
tion
sup
port
ed
ex
pert
opin
ion
gen
er
al
ly
epi
demi
olog
cal
data
use
usu
al
care
rel
tive
risk
duc
tion
rel
tive
improv
ment
ap
pli
es
ti
mate
event
os
eltamivirand
zanamivirtreat
ed
patient
coun
trysp
cif
ic
sourc
use
cost
data
col
lect
ed
sep
rate
ly
pub
lish
sourc
ta
ble
pre
sent
main
prob
bil
tie
use
anal
si
two
com
pli
cation
clud
ed
anal
si
bron
chiti
pneu
mo
nia
cho
sen
caus
strong
ci
tion
flu
en
za
high
ci
denc
ap
pli
ca
bili
ty
cho
sen
pop
u
la
tion
group
mod
el
sume
di
vid
u
al
de
vel
op
sin
gle
com
pli
ca
tion
un
der
ly
ing
data
epi
demi
log
cal
stud
i
pro
vide
ci
denc
compli
ca
tion
pub
lish
mation
whether
di
vid
u
al
u
al
prob
bil
tie
hav
ing
fluen
zalik
ill
ness
ili
de
vel
op
ing
ilir
lat
ed
com
pli
ca
tion
pneu
mo
nia
bron
chi
ti
pa
tient
without
com
pli
ca
tion
mod
el
describ
three
di
eas
state
pa
tient
symp
tom
ic
fec
tion
sult
outpa
tient
treat
ment
pri
ry
sec
tor
pa
tient
symp
tom
ic
fec
tion
result
ho
pi
tal
iza
tion
clud
ing
patient
treat
ment
preand
postho
pi
tal
izat
death
symp
tom
ic
fec
tion
sult
death
death
lat
ed
ili
com
pli
ca
tion
clud
ed
mod
el
clud
ing
pa
tient
inpa
tient
treat
ment
fore
death
di
eas
state
ap
pli
ili
ca
es
ie
influ
en
za
vi
ru
po
tive
well
flu
en
za
vi
ru
neg
tive
ca
es
sim
lar
branch
es
rep
sent
ed
plu
sign
mod
el
struc
ture
mod
el
base
pub
lish
epi
demio
log
cal
clin
cal
tri
al
data
medlin
search
per
form
cov
er
ing
va
rieti
epi
demi
log
calm
cal
well
health
eco
nom
ic
key
word
year
flu
en
za
treat
ment
plu
sign
sim
lar
branch
es
mod
el
struc
ture
ie
mod
el
struc
ture
right
flu
en
za
po
tive
flu
en
za
neg
tive
mod
el
struc
ture
right
treat
ment
start
h
treat
ment
start
h
bil
ty
pa
tient
di
con
tin
ue
treatment
feel
bet
ter
devel
op
ga
tro
te
ti
nal
side
ef
fect
un
der
oseltamivir
treat
ment
al
readi
clud
ed
un
der
ly
ing
clin
cal
tri
al
data
intend
treat
pop
u
la
tion
use
drug
side
ef
fect
usu
al
ly
mild
selflim
ing
ie
sourc
use
ci
ed
im
pact
side
ef
fect
qual
ty
life
al
readi
clude
dai
ly
qual
ty
life
port
ed
clin
cal
tri
al
studi
clude
sess
ment
di
rect
med
cal
cost
health
care
pay
er
per
spectiv
also
pro
duc
tiv
ty
loss
due
sick
leav
base
unit
cost
year
ta
ble
di
rect
health
care
cost
use
mod
el
clude
drug
use
cost
prima
ry
sec
ond
ari
care
sourc
cost
com
pre
hen
sive
unit
ed
state
databas
nation
al
bu
la
ry
med
cal
care
sur
vey
nam
cs
use
de
vel
op
es
timat
sourc
use
com
pli
cation
clud
ing
gp
spe
cial
ist
vi
test
ve
ti
ga
tion
drug
data
lev
el
de
tail
avail
abl
specif
ical
ly
uk
nam
cs
data
pro
vide
rate
drug
pre
scrib
ing
com
pli
ca
tion
well
drug
class
rate
ti
bi
ot
ic
pre
scrib
ing
nam
cs
databas
strik
ing
ly
sim
lar
pub
lish
es
ti
mate
uk
ex
ple
mei
er
et
al
port
ap
prox
com
pli
cat
ed
flu
enza
ca
es
uk
treat
ed
ti
biot
ic
nam
cs
es
ti
mate
uncom
pli
cat
ed
flu
en
za
ca
es
rate
spec
tive
ly
pro
duc
tiv
ty
loss
val
u
ap
pli
ing
hu
man
capi
tal
ap
proach
thu
us
ing
time
turn
mal
ac
tiv
ty
day
eval
u
ed
epidemi
log
cal
stud
i
clin
cal
tri
al
valu
ing
time
av
er
age
gross
uk
come
time
turn
mal
ac
tiv
ty
cho
sen
ef
fec
tive
ness
mea
sure
sinc
mea
sure
mean
ing
pa
tient
well
em
ploy
er
de
ci
sion
mak
er
al
le
vi
tion
fe
ver
symp
tom
cap
ture
part
diseas
pic
ture
turn
mal
ac
tivi
ty
ing
mea
sure
best
cap
ture
flu
en
za
treat
ment
neur
amin
dase
hibitor
costef
fec
tive
ness
costutil
ty
heal
thi
adult
unit
ed
king
dom
ab
stract
sess
costef
fec
tive
ness
costutil
ty
treat
ing
flu
en
za
neur
amini
dase
hibitor
os
eltamivir
zanamivir
health
care
pay
er
ci
etal
per
spec
tive
unit
ed
king
dom
sim
ula
tion
mod
el
de
vel
ope
pre
dict
morbid
ty
mor
tal
ty
due
flu
en
za
spec
fie
com
pli
ca
tion
com
par
ing
neuramin
dase
hibitor
usu
al
care
oth
er
wise
heal
thi
adult
pop
u
la
tion
ro
bust
sult
test
ed
oneway
mul
ti
way
well
prob
bili
tic
sen
sitiv
ty
anal
se
treat
ment
ei
ther
neuramin
dase
hib
tor
sult
duce
morbid
ty
faster
turn
mal
ac
tiv
tie
ev
er
os
eltamivir
dom
nate
zanamivir
costutil
ty
anal
si
due
low
er
cost
com
par
ing
os
eltamivir
usu
al
care
cost
per
day
mal
ac
tiv
ty
gain
per
qual
tyad
ed
lifeyear
gain
health
care
pay
er
perspec
tive
os
eltamivir
dom
nate
usu
al
care
ci
etal
per
spec
tive
treat
ment
os
eltamivir
costef
fec
tive
strat
e
gy
oth
er
wise
heal
thi
adult
uk
health
care
pay
er
ci
etal
perspec
tive
flu
en
za
treat
ment
tivi
ral
costef
fec
tive
ness
de
ci
sion
mod
el
ing
cure
di
eas
tal
dura
tion
ill
ness
time
turn
mal
ac
tiv
ty
cho
sen
mor
tal
ty
mea
sure
effec
tive
ness
mor
tal
ty
low
healthi
adult
fore
end
point
clin
cal
tri
al
heal
thi
adult
pop
ula
tion
main
goal
treat
ing
heal
thi
adult
store
pa
tient
health
fast
po
si
ble
fur
ther
mor
tal
ty
clud
ed
qual
ty
ad
ed
life
year
time
turn
mal
ac
tiv
ty
sec
ond
ari
clin
cal
end
point
oseltamivir
tri
al
mea
sure
us
ing
lik
erttyp
scale
end
point
turn
mal
ac
tivi
ty
mal
ac
tiv
ty
de
fine
usu
al
abil
ty
car
ry
mal
ac
tiv
tie
cours
de
pen
dent
di
vid
u
al
hisher
ter
pre
ta
tion
healthi
adult
tri
al
pa
tient
turn
mal
ac
tiv
ty
day
fol
lowup
pe
ri
od
af
ter
treat
ment
start
ev
er
mean
strict
ed
mean
pa
tient
turn
mal
ac
tivi
tie
fore
last
tri
al
mea
sure
ment
mean
pa
tient
turn
ing
normal
ac
tiv
ty
day
cen
sore
zanamivir
tri
al
ev
er
port
ed
di
du
ra
tion
day
turn
normal
ac
tiv
ty
day
pla
ce
bo
vs
day
zanamivir
duc
tion
pa
tient
record
ed
symp
tom
tem
per
ture
abil
ty
per
form
mal
dai
ly
ac
tivi
tie
di
ari
card
day
symptom
per
sist
ed
day
avoid
ed
death
im
prove
qual
iti
life
giv
en
sin
gle
val
ue
us
ing
ap
proach
qual
tyad
ed
lifeyear
qali
qual
ty
weight
sign
health
state
ad
ed
time
pa
tient
spend
state
qual
ty
weight
val
ue
tween
death
per
fect
health
qual
ty
weight
de
rive
lit
er
ture
di
eas
clud
ed
anal
si
flu
en
za
bron
chi
ti
pneumo
nia
sourc
use
en
sure
con
si
ten
cy
tween
weight
gener
cal
ly
de
rive
qual
ty
weight
mean
also
con
sistent
qual
ty
weight
var
ou
oth
er
di
eas
heart
di
eas
cer
sinc
qual
ty
life
vari
tween
dif
fer
ent
treat
ment
op
tion
flu
enza
sult
clin
cal
tri
al
roch
use
es
ti
mate
rel
tive
im
provement
qual
ty
life
tween
pla
ce
bo
os
eltamivir
dur
ing
first
day
flu
en
za
ep
sode
ap
proach
cent
nice
sess
ment
use
im
prove
ment
qual
ty
life
tween
pla
ce
bo
os
eltamivir
es
timat
ed
pa
tient
health
state
val
u
tion
port
ed
dai
ly
day
os
eltamivir
clin
cal
tri
al
qali
gen
er
ed
recal
brat
ing
roch
lik
ert
score
mean
vsu
al
logu
scale
va
score
tran
form
ing
time
tradeoff
equiv
lent
score
de
scrip
tion
tran
tion
see
rel
tive
improv
ment
oth
er
wise
heal
thi
adult
pop
u
la
tion
ap
pli
ge
ner
ic
fluen
za
qual
ty
weight
de
rive
qual
ty
weight
ili
pa
tient
ef
fec
tive
ly
treat
os
eltamivir
data
avail
qual
ty
life
im
prove
ment
zanamivir
im
prove
ment
oseltamivir
sume
sim
u
lat
ed
pa
tient
fol
low
mod
el
di
vid
u
al
ly
sinc
divid
u
al
pa
tient
sin
gle
state
giv
en
time
pass
one
branch
tree
giv
en
chanc
node
fig
henc
path
fol
low
dif
fer
ent
pa
tient
dif
fer
due
chanc
larg
num
ber
pa
tient
cho
sen
caus
larg
num
ber
endpoint
small
prob
bil
tie
mod
el
es
pe
cial
ly
mor
tal
ty
indi
vid
u
al
sim
u
la
tion
meth
od
es
ti
mate
like
ly
vari
anc
lat
ed
sim
pli
ent
un
cer
tain
ty
prob
bili
tic
struc
ture
mod
el
pa
tient
vari
abil
iti
sec
ondor
der
montecar
lo
sim
u
la
tion
mod
el
deal
un
cer
tain
ty
lat
ed
put
vari
abl
us
ing
prob
bil
ty
di
tribu
tion
around
point
val
ue
mean
ad
di
tion
al
low
ing
vari
abil
ty
due
way
di
vid
ual
trav
el
mod
el
firstor
der
mont
car
lo
sim
u
la
tion
un
der
ly
ing
mod
el
vari
abl
al
low
vari
giv
en
rang
giv
en
di
tri
bu
tion
sim
u
la
tion
run
val
ue
distri
bu
tion
vari
abl
pick
random
gen
er
ing
one
set
put
cost
ef
fec
tive
ness
larg
num
ber
simu
la
tion
run
fore
yield
di
tri
bu
tion
put
caus
po
si
ble
im
pact
un
cer
tain
ty
sur
round
ing
cer
tain
vari
abl
cho
sen
pre
de
fine
di
tri
bu
tion
prob
bil
tie
com
pli
ca
tion
ho
pi
tal
iza
tion
mor
tal
ty
du
ra
tion
day
turn
mal
activ
ty
length
stay
ho
pi
tal
beta
distri
bu
tion
prob
bil
tie
gam
distri
bu
tion
du
ra
tion
use
pa
tient
ran
dom
ly
tra
ver
es
sin
gle
path
mod
el
mod
el
cal
cu
lat
ed
time
cre
men
tal
costef
fec
tive
ness
costutil
ty
anal
se
pro
vid
ed
ad
di
tion
al
cost
ad
di
tional
health
come
ci
ed
scenar
io
com
pare
two
per
spec
tive
ve
ti
gat
ed
health
care
pay
er
ci
eti
hu
man
cap
tal
ap
proach
base
av
er
age
come
use
val
ue
pa
tient
abil
ty
work
due
ill
ness
avoid
dou
ble
count
ing
costutil
ty
anal
si
direct
cost
due
pre
ture
mor
tal
ty
clud
ed
sinc
cap
ture
mea
sure
health
come
qali
com
par
son
cost
also
ex
clud
ed
costef
fec
tive
ness
anal
si
cost
ef
fect
lat
ed
flu
enza
oc
cur
year
oc
cur
fu
ture
year
life
lost
due
pre
matur
death
fore
sult
anal
ysi
pre
sent
ed
di
count
ed
us
ing
discount
rate
health
come
year
life
lost
per
num
rec
ommend
ed
eco
nom
ic
eval
u
tion
health
care
field
uk
base
case
de
fine
hav
ing
di
ag
no
tic
cer
tain
ty
rate
treatment
start
h
set
symptom
oneway
sen
si
tiv
ty
anal
se
present
ed
two
vari
abl
gen
er
al
ly
liev
jor
im
pact
result
di
ag
no
tic
cer
tain
ty
time
treatment
start
af
ter
set
symp
tom
di
agno
tic
cer
tain
ty
de
scribe
per
cent
age
flu
en
zapo
tive
pa
tient
ili
pop
u
la
tion
pre
sum
abli
higher
flu
en
za
cir
cu
lat
ing
base
case
sce
nario
di
ag
no
tic
cer
tain
ty
sume
point
es
ti
mate
sump
tion
made
base
di
ag
nostic
cer
tain
ty
rate
around
ob
serv
os
eltamivir
clin
cal
tri
al
draw
ing
anal
se
pub
lish
zanamivir
tech
nol
gy
sess
ment
cho
sen
low
es
ti
mate
di
ag
no
tic
cer
tain
ty
sen
si
tiv
ty
anal
si
sinc
time
treatment
start
h
set
symp
tom
treat
ment
neur
amini
dase
hibitor
ef
fec
tive
sumption
made
pa
tient
hav
ing
gp
con
sul
ta
tion
pe
ri
od
ceiv
neur
amin
dase
hibitor
sen
si
tiv
iti
anal
si
im
pact
pro
por
tion
pa
tient
ceiv
ing
neur
amin
dase
inhibitor
af
ter
h
symp
tom
evalu
ed
clin
cal
tri
al
like
ly
control
fac
tor
al
readi
extent
ev
er
im
pact
patient
ceiv
ing
treat
ment
ex
cess
h
af
ter
symp
tom
set
test
ed
repr
sent
ar
bi
trari
pro
por
tion
late
presen
ter
ceiv
ing
treat
ment
help
demon
strate
sen
si
tiv
ty
sult
vari
abl
mul
ti
way
sen
si
tiv
ty
anal
si
sum
ing
neur
amin
dase
hibitor
ef
fect
ho
pi
tal
iza
tion
com
pli
ca
tion
mortal
ty
low
di
ag
no
tic
cer
tain
ty
rate
per
form
come
measur
clud
ed
vari
ing
de
gree
oth
er
pu
bli
ca
tion
mean
ef
fect
cap
ture
duc
tion
day
turn
mal
ac
tiv
ty
im
prove
ment
qual
ty
life
typ
cal
pa
tient
ep
sode
flu
en
za
ad
dition
al
sen
si
tiv
ty
anal
si
show
sult
exclud
ing
ho
pi
tal
iza
tion
com
pli
ca
tion
mor
tal
ty
stra
te
gie
usu
al
care
os
eltamivir
zanamivir
di
agno
tic
cer
tain
ty
rate
life
year
lost
due
pre
ture
death
di
count
ed
di
count
rate
fore
ex
pect
ed
small
im
pact
sult
ev
er
undiscount
ed
anal
si
per
form
day
lost
time
turn
mal
ac
tiv
ty
val
u
us
ing
hu
man
cap
tal
approach
ap
proach
flect
valu
heal
thi
time
fore
gone
ie
also
val
ue
mi
sing
leisur
time
time
return
mal
ac
tiv
ty
use
base
case
anal
si
seem
long
com
pare
oth
er
stud
i
eval
u
ing
pro
duc
tivi
ty
loss
sen
si
tiv
ty
anal
si
therefor
per
form
valu
ing
pro
duc
tiv
ty
loss
sum
ing
pa
tient
time
turn
mal
ac
tivi
tie
pro
duc
tiv
ty
loss
patient
week
end
would
usu
al
ly
ie
sick
leisur
time
fore
work
loss
ta
ble
pre
sent
ex
pect
ed
cost
ben
e
fit
base
case
sce
nario
treat
ment
oth
er
wise
heal
thi
adult
health
care
pay
er
per
spec
tive
oseltamivir
ci
ed
greater
overal
ben
e
fit
zanamivir
usu
al
care
greater
mean
ex
pect
ed
cost
per
pa
tient
usu
al
care
low
er
mean
ex
pect
cost
per
pa
tient
zanamivir
differ
enc
cost
tween
zanamivir
os
eltamivir
due
main
ly
high
er
price
zanamivir
also
high
er
rate
pneu
mo
nia
zanamivir
os
eltamivir
fore
dom
nate
zanamivir
cost
utili
ty
anal
si
cre
men
tal
cost
per
day
mal
ac
tiv
ty
gain
os
eltamivir
com
par
son
usu
al
care
mini
mum
max
mum
mean
ex
pect
ed
cre
men
tal
cost
per
di
count
ed
qali
min
mum
max
mum
usu
al
care
dom
nant
fig
ure
pre
sent
costef
fec
tive
ac
cept
abil
ty
curv
com
par
ison
os
eltamivir
usu
al
care
health
care
pay
er
per
spec
tive
gen
er
ed
prob
bilist
anal
se
show
ing
lev
el
un
cer
tainti
around
base
case
es
ti
mate
costeffec
tive
ness
prob
bil
ty
os
eltamivir
ing
costef
fec
tive
oth
er
wise
healthi
adult
pop
u
la
tion
sume
cost
per
qali
ceil
ing
anali
se
also
con
duct
ed
ci
etal
per
spec
tive
ta
ble
os
eltamivir
dom
inat
usu
al
care
also
zanamivir
costutil
ty
anal
si
ac
cru
ing
ben
e
fit
per
pa
tient
less
cost
sult
oneway
mul
ti
way
sen
si
tivi
ty
anal
se
pre
sent
ed
com
pari
son
os
eltamivir
usu
al
care
sinc
zanamivir
dom
nat
ed
os
eltamivir
sen
si
tiv
ty
anal
se
caus
zanamivir
ex
pen
sive
os
eltamivir
uk
two
neur
amin
dase
inhibitor
sim
lar
way
ac
tion
effec
tive
ness
im
pact
low
er
lev
el
di
ag
no
tic
cer
tain
ty
upon
cre
men
tal
costef
fec
tive
ness
os
eltamivir
compar
usu
al
care
see
ta
ble
nh
per
spec
tive
anal
se
demonstr
sult
sen
si
tive
lev
el
di
ag
no
tic
cer
tain
ty
sume
lev
el
di
ag
no
tic
cer
tain
ty
reduc
cre
men
tal
costef
fec
tive
ness
ra
tio
os
eltamivir
creas
also
seen
shift
costac
ceptabil
ty
curv
right
see
fig
ev
er
os
eltamivir
main
costef
fectiv
term
cre
men
tal
cost
per
qali
gain
health
care
pay
er
per
spec
tive
thresh
old
gain
dom
nant
ci
etal
per
spec
tive
even
sum
ing
di
ag
no
tic
cer
tain
ty
im
pact
time
treat
ment
ini
ti
ation
costef
fec
tive
ness
sult
also
sess
ta
ble
base
case
sume
pa
tient
treat
ed
os
eltamivir
start
treat
ment
h
symp
tom
set
sen
si
tiv
ty
time
turn
mal
ac
tiv
ty
per
pa
tient
day
cost
per
day
mal
ac
tiv
ty
gain
health
care
pay
er
per
spec
tive
os
eltamivir
main
costef
fectiv
even
pa
tient
ceiv
ing
ben
e
fit
flu
en
za
neg
tive
plu
late
pre
sen
ter
among
flu
en
za
po
tive
pa
tient
mul
ti
way
sen
si
tivi
ty
anal
si
omit
ting
ef
fect
lat
ed
ho
pi
tal
iza
tion
com
pli
ca
tion
mortal
ty
sum
ing
low
di
ag
no
tic
certain
ty
rate
os
eltamivir
still
cost
ef
fec
tive
nh
point
view
dom
nate
usu
al
care
ci
etal
point
view
ex
pect
ed
di
count
ing
small
im
pact
sult
low
er
work
loss
sume
sensi
tiv
ty
anal
si
flu
en
za
un
com
fort
abl
con
di
tion
sever
ly
af
fect
qual
ty
life
rela
tive
ly
short
pe
ri
od
un
com
pli
cat
ed
selflim
ing
ca
es
ev
er
view
lit
er
ture
sug
gest
ac
tu
al
knowl
edg
flu
en
za
con
se
quenc
health
health
care
sourc
use
econ
lim
ite
part
mod
el
tri
captur
rel
e
vant
pub
lish
knowl
edg
di
eas
im
pli
ca
tion
ev
er
con
text
de
ci
sion
mak
ing
pro
vid
ing
treat
ment
neur
amin
dase
hibitor
flu
en
za
im
por
tant
un
der
stand
sult
pre
sent
ed
con
di
tion
al
base
line
prob
abil
tie
use
mod
el
mod
el
sub
ject
num
ber
lim
ta
tion
gener
al
lack
ac
cu
rate
mation
flu
en
za
com
pli
ca
tion
mortal
ty
ho
pi
tal
iza
tion
rate
wise
heal
thi
adult
pop
u
la
tion
baselin
prob
bil
tie
flu
en
za
com
pli
cation
mor
tal
ty
ho
pi
tal
iza
tion
rather
pu
bli
ca
tion
due
rel
tive
ly
lim
ed
knowl
edg
true
com
pli
ca
tion
mor
tal
ty
rate
ciat
ed
flu
en
za
also
worth
ing
base
line
prob
bil
tie
base
ili
con
firm
flu
en
za
ca
es
po
si
ble
fil
ter
ili
case
due
oth
er
pathogen
eg
re
pi
ra
tori
syn
cy
tial
vi
ru
parain
fluen
za
viru
coro
na
vi
ru
true
flu
en
za
ca
es
base
line
prob
bil
tie
would
like
ly
high
er
de
spite
avail
abil
ty
rapid
influ
en
za
test
test
ing
rou
tine
ly
carri
costef
fec
tive
base
line
prob
bil
tie
flect
flu
enza
sea
son
stud
i
conduct
ed
ter
pan
dem
ic
sea
son
mean
case
par
tic
u
lar
ly
strong
flu
en
za
epi
dem
ic
pan
dem
ic
base
line
ci
denc
rate
com
pli
ca
tion
mor
tal
ty
ho
pital
iza
tion
would
prob
bli
sub
stan
tial
ly
high
er
would
cer
tain
ty
di
ag
nosi
henc
sult
ing
costef
fec
tive
treat
ment
would
even
favor
abl
sum
ing
treat
ment
effect
due
data
lim
ta
tion
also
clude
ho
pi
tal
iza
tion
due
bronchi
ti
clude
cer
tain
oth
er
second
ari
com
pli
ca
tion
eg
asth
mat
ic
exac
er
ba
tion
car
di
ac
event
ev
er
ex
clu
sion
event
mod
el
like
ly
gen
er
ate
con
ser
vativ
es
ti
mate
ben
e
fit
flu
en
za
treat
ment
anal
si
also
lim
ed
availabil
ty
ac
cu
rate
uk
med
cal
sourc
use
data
col
lect
ed
alongsid
clin
cal
tri
al
es
ti
mate
resourc
use
base
part
ly
upon
nonuk
sourc
data
com
bine
uksp
cif
ic
unit
cost
data
avail
abl
base
upon
ret
ro
spec
tive
anal
si
patient
record
uk
clu
sion
data
nam
cs
flect
de
tail
break
sourc
use
com
pli
ca
tion
sim
lar
ty
ag
gregat
data
sourc
use
com
pa
ra
ble
uk
sourc
oth
er
hand
model
cap
ture
much
flu
en
za
ill
ness
po
si
ble
giv
en
pub
lish
data
use
prob
bili
tic
mod
el
ing
tak
ing
account
un
cer
tain
ty
per
tain
ing
com
pli
ca
tion
ho
pi
tal
iza
tion
mor
tali
ty
rate
du
ra
tion
day
turn
mal
ac
tiv
ty
length
stay
ho
pi
tal
drive
dy
nam
ic
flu
en
za
flu
en
za
treat
ment
pa
tient
pref
er
enc
ob
tain
clin
cal
tri
al
us
ing
rat
ing
scale
op
pose
stan
dard
gam
ble
meth
od
que
tion
frame
un
der
cer
tain
ty
sub
ject
ask
per
form
scal
ing
task
base
tro
spec
tion
therefor
rat
ing
scale
meth
od
requir
sub
ject
choos
tween
al
terna
tive
cap
ture
sub
ject
risk
ti
tude
search
shown
standard
gam
ble
score
high
er
time
tradeoff
score
high
er
visu
al
logu
score
bi
es
port
ed
lat
ed
rat
ing
scale
endofscal
bia
sub
ject
tend
use
end
scale
space
bia
sub
ject
tend
space
come
scale
howev
er
rat
ing
scale
meth
od
wide
ly
ac
cept
ed
meth
od
mea
sur
ing
pa
tient
pref
er
enc
quick
ef
fi
cient
rat
ing
scale
con
vert
ed
time
tradeoff
score
us
ing
pow
ercurv
con
ver
sion
day
mal
ac
tiv
ty
gain
use
di
easesp
cif
ic
come
enabl
us
make
com
par
ison
tween
ter
ven
tion
un
der
con
sid
er
tion
ev
er
ter
pret
ing
sult
straight
ward
port
net
cost
day
mal
ac
tiv
ty
gain
os
eltamivir
com
pare
usu
al
care
oth
er
wise
heal
thi
adult
gen
eral
day
mal
ac
tiv
ty
healthi
adult
pop
u
la
tion
like
ly
pre
ent
good
val
ue
mon
ey
sum
ing
ear
li
er
turn
work
av
er
age
gross
dai
ly
wage
ap
prox
pre
ent
sim
u
la
tion
sult
us
ing
mean
min
mum
max
mum
valu
costef
fec
tive
ness
ra
tio
caus
prob
lem
lat
ed
ex
press
ing
stocha
tic
un
cer
tain
ty
sur
round
ing
costef
fec
tive
ness
ra
tio
main
prob
lem
di
con
tin
u
ou
di
tri
bu
tion
costef
fec
tive
ness
ra
tio
sev
er
al
method
es
ti
mat
ing
con
fi
denc
ter
val
costef
fec
tive
ness
ra
tio
propos
po
ing
method
olog
cal
challeng
one
al
ter
na
tive
ap
proach
es
use
ac
cept
abil
ty
curv
also
pre
sent
ed
anal
si
sume
costef
fec
tive
ness
ra
tio
symmet
ri
cal
point
cor
spond
point
es
ti
mate
costef
fec
tive
ness
ra
tio
fur
ther
curv
increas
mono
ton
cal
ly
cut
ting
either
end
ver
ti
cal
axi
us
ing
curv
map
val
ue
hor
izon
tal
axi
de
fine
con
fi
denc
inter
val
ev
er
lim
ta
tion
method
pref
er
enc
gain
loss
es
fact
sym
met
ri
cal
ie
point
would
cor
spond
mean
val
ue
cre
men
tal
costef
fec
tive
ness
ra
tio
im
por
tant
con
sid
er
sult
con
text
oth
er
pub
lish
costeffec
tive
ness
anal
se
flu
en
za
treat
ment
uk
anal
se
pre
sent
ed
cent
guid
anc
gard
ing
use
os
eltamivir
zanamivir
aman
ta
dine
nice
port
cre
men
tal
cost
per
qali
os
eltamivir
zanamivir
amanta
dine
com
pare
usual
care
base
case
sum
ing
diag
no
tic
cer
tain
ty
im
pact
hospi
tal
iza
tion
mor
tal
ty
oth
erwis
heal
thi
adult
pop
u
la
tion
sen
sitiv
ty
anal
si
al
ter
na
tive
mod
el
spec
fica
tion
di
ag
no
tic
cer
tain
ty
show
fol
low
ing
cre
men
tal
cost
per
qali
com
pare
usu
al
care
aman
ta
dine
os
eltamivir
zanamivir
com
pa
ra
ble
result
pre
sent
ed
studi
giv
en
pre
ent
pub
lish
knowl
edg
flu
en
za
di
eas
ci
ed
com
pli
ca
tion
anal
si
found
oseltamivir
costef
fec
tive
treat
ment
flu
en
za
com
pare
usu
al
care
zanamivir
oth
er
wise
heal
thi
adult
pop
u
la
tion
cre
men
tal
costef
fec
tive
ra
tio
com
par
ing
os
eltamivir
usu
al
care
per
day
ac
tiv
ty
gain
health
care
pay
er
per
spec
tive
prob
bilist
mod
el
ing
use
ex
plore
un
certain
ty
around
base
case
mean
ex
pect
costef
fec
tive
ness
ra
tio
demon
strate
sim
u
lat
ed
es
ti
mate
con
si
tent
con
clu
sion
os
eltamivir
cost
